SEARCH

SEARCH BY CITATION

References

  • Arancio O., Zhang H. P., Chen X. et al. (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 23, 40964105.
  • Balducci C., Beeg M., Stravalaci M. et al. (2010) Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc. Natl. Acad. Sci. USA 107, 22952300.
  • Barghorn S., Nimmrich V., Striebinger A. et al. (2005) Globular amyloid beta-peptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J. Neurochem. 95, 834847.
  • Barry A. E., Klyubin I., Mc Donald J. M., Mably A. J., Farrell M. A., Scott M., Walsh D. M. and Rowan M. J. (2011) Alzheimer’s disease brain-derived amyloid-{beta}-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J. Neurosci. 31, 72597263.
  • Benilova I. and De Strooper B. (2010) Prion protein in Alzheimer’s pathogenesis: a hot and controversial issue. EMBO Mol. Med. 2, 289290.
  • Bhaskar K., Yen S. H. and Lee G. (2005) Disease-related modifications in tau affect the interaction between Fyn and Tau. J. Biol. Chem. 280, 3511935125.
  • Bhaskar K., Hobbs G. A., Yen S. H. and Lee G. (2010) Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol. Appl. Neurobiol. 36, 462477.
  • Calella A. M., Farinelli M., Nuvolone M., Mirante O., Moos R., Falsig J., Mansuy I. M. and Aguzzi A. (2010) Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol. Med. 2, 306314.
  • Chang L., Bakhos L., Wang Z., Venton D. L. and Klein W. L. (2003) Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer’s disease drug candidate screening. J. Mol. Neurosci. 20, 305313.
  • Cheng I. H., Scearce-Levie K., Legleiter J. et al. (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282, 2381823828.
  • Chin J., Palop J. J., Yu G. Q., Kojima N., Masliah E. and Mucke L. (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J. Neurosci. 24, 46924697.
  • Chin J., Palop J. J., Puolivali J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E. and Mucke L. (2005) Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer’s disease. J. Neurosci. 25, 96949703.
  • Cisse M., Halabisky B., Harris J. et al. (2011a) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 4752.
  • Cisse M., Sanchez P. E., Kim D. H., Ho K., Yu G. Q. and Mucke L. (2011b) Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the j20 line of human amyloid precursor protein transgenic mice. J. Neurosci. 31, 1042710431.
  • Cleary J. P., Walsh D. M., Hofmeister J. J., Shankar G. M., Kuskowski M. A., Selkoe D. J. and Ashe K. H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8, 7984.
  • Dalva M. B., Takasu M. A., Lin M. Z., Shamah S. M., Hu L., Gale N. W. and Greenberg M. E. (2000) EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 103, 945956.
  • Deane R., Du Yan S., Submamaryan R. K. et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat. Med. 9, 907913.
  • Deshpande A., Mina E., Glabe C. and Busciglio J. (2006) Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 26, 60116018.
  • Dewachter I., Filipkowski R. K., Priller C. et al. (2009) Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol. Aging 30, 241256.
  • Dickson D. W., Crystal H. A., Bevona C., Honer W., Vincent I. and Davies P. (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16, 285298; discussion 298–304.
  • Eckert A., Hauptmann S., Scherping I. et al. (2008) Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J. Mol. Med. 86, 12551267.
  • Freir D. B., Nicoll A. J., Klyubin I. et al. (2011) Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2, 336.
  • Georganopoulou D. G., Chang L., Nam J. M., Thaxton C. S., Mufson E. J., Klein W. L. and Mirkin C. A. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 102, 22732276.
  • Glabe C. G. (2008) Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 2963929643.
  • Glabe C. G. and Kayed R. (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66, S74S78.
  • Gong Y., Chang L., Viola K. L., Lacor P. N., Lambert M. P., Finch C. E., Krafft G. A. and Klein W. L. (2003) Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 1041710422.
  • Haass C. and Mandelkow E. (2010) Fyn-tau-amyloid: a toxic triad. Cell 142, 356358.
  • Hardy J. A. and Higgins G. A. (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184185.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Hillen H., Barghorn S., Striebinger A. et al. (2010) Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J. Neurosci. 30, 1036910379.
  • Ittner L. M. and Gotz J. (2011) Amyloid-beta and tau – a toxic pas de deux in Alzheimer’s disease. Nat. Rev. Neurosci. 12, 6572.
  • Ittner L. M., Ke Y. D., Delerue F. et al. (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142, 387397.
  • Jin M., Shepardson N., Yang T., Chen G., Walsh D. and Selkoe D. J. (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. USA 108, 58195824.
  • Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H. and Younkin S. G. (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J. Neurosci. 21, 372381.
  • Kawarabayashi T., Shoji M., Younkin L. H. et al. (2004) Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer’s disease. J. Neurosci. 24, 38013809.
  • Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W. and Glabe C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486489.
  • Kayed R., Pensalfini A., Margol L., Sokolov Y., Sarsoza F., Head E., Hall J. and Glabe C. (2009) Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem. 284, 42304237.
  • Kessels H. W., Nguyen L. N., Nabavi S. and Malinow R. (2010) The prion protein as a receptor for amyloid-beta. Nature 466, E3E4; discussion E4–E5.
  • Kim S. I., Yi J. S. and Ko Y. G. (2006) Amyloid beta oligomerization is induced by brain lipid rafts. J. Cell. Biochem. 99, 878889.
  • Kokubo H., Kayed R., Glabe C. G., Staufenbiel M., Saido T. C., Iwata N. and Yamaguchi H. (2009) Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification. Int. J. Alzheimers Dis. 2009, 689285.
  • Lacor P. N., Buniel M. C., Chang L. et al. (2004) Synaptic targeting by Alzheimer’s-related amyloid beta oligomers. J. Neurosci. 24, 1019110200.
  • Lacor P. N., Buniel M. C., Furlow P. W., Clemente A. S., Velasco P. T., Wood M., Viola K. L. and Klein W. L. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J. Neurosci. 27, 796807.
  • Lambert M. P., Barlow A. K., Chromy B. A. et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U S A 95, 64486453.
  • Lambert M. P., Velasco P. T., Chang L. et al. (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J. Neurochem. 100, 2335.
  • Lasagna-Reeves C. A., Glabe C. G. and Kayed R. (2011) Amyloid-{beta} annular protofibrils evade fibrillar fate in alzheimer disease brain. J. Biol. Chem. 286, 2212222130.
  • Lashuel H. A. and Lansbury Jr P. T. (2006) Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39, 167201.
  • Lauren J., Gimbel D. A., Nygaard H. B., Gilbert J. W. and Strittmatter S. M. (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 11281132.
  • Lee G., Newman S. T., Gard D. L., Band H. and Panchamoorthy G. (1998) Tau interacts with src-family non-receptor tyrosine kinases. J. Cell Sci. 111(Pt 21), 31673177.
  • Lee G., Thangavel R., Sharma V. M. et al. (2004) Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J. Neurosci. 24, 23042312.
  • Leon W. C., Canneva F., Partridge V. et al. (2010) A novel transgenic rat model with a full Alzheimer’s-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J. Alzheimers Dis. 20, 113126.
  • Lesne S., Koh M. T., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M. and Ashe K. H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352357.
  • Lesne S., Kotilinek L. and Ashe K. H. (2008) Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151, 745749.
  • Li S., Hong S., Shepardson N. E., Walsh D. M., Shankar G. M. and Selkoe D. (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788801.
  • Li S., Jin M., Koeglsperger T., Shepardson N. E., Shankar G. M. and Selkoe D. J. (2011) Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 31, 66276638.
  • Lue L. F., Kuo Y. M., Roher A. E. et al. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am. J. Pathol. 155, 853862.
  • Ma H., Lesne S., Kotilinek L. et al. (2007) Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. USA 104, 81678172.
  • Mc Donald J. M., Savva G. M., Brayne C., Welzel A. T., Forster G., Shankar G. M., Selkoe D. J., Ince P. G. and Walsh D. M. (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133, 13281341.
  • McLean C. A., Cherny R. A., Fraser F. W., Fuller S. J., Smith M. J., Beyreuther K., Bush A. I. and Masters C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann. Neurol. 46, 860866.
  • Meilandt W. J., Cisse M., Ho K., Wu T., Esposito L. A., Scearce-Levie K., Cheng I. H., Yu G. Q. and Mucke L. (2009) Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J. Neurosci. 29, 19771986.
  • Mucke L., Masliah E., Yu G. Q. et al. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 40504058.
  • Nimmrich V., Grimm C., Draguhn A. et al. (2008) Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J. Neurosci. 28, 788797.
  • Oddo S., Caccamo A., Tran L., Lambert M. P., Glabe C. G., Klein W. L. and LaFerla F. M. (2006) Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 281, 15991604.
  • O’Nuallain B., Freir D. B., Nicoll A. J., Risse E., Ferguson N., Herron C. E., Collinge J. and Walsh D. M. (2010) Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J. Neurosci. 30, 1441114419.
  • Origlia N., Righi M., Capsoni S. et al. (2008) Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J. Neurosci. 28, 35213530.
  • Podlisny M. B., Ostaszewski B. L., Squazzo S. L., Koo E. H., Rydell R. E., Teplow D. B. and Selkoe D. J. (1995) Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270, 95649570.
  • Podlisny M. B., Walsh D. M., Amarante P., Ostaszewski B. L., Stimson E. R., Maggio J. E., Teplow D. B. and Selkoe D. J. (1998) Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 37, 36023611.
  • Puzzo D., Privitera L., Leznik E., Fa M., Staniszewski A., Palmeri A. and Arancio O. (2008) Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J. Neurosci. 28, 1453714545.
  • Reed M. N., Hofmeister J. J., Jungbauer L. et al. (2009) Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol. Aging 31, 169179.
  • Renner M., Lacor P. N., Velasco P. T., Xu J., Contractor A., Klein W. L. and Triller A. (2010) Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 66, 739754.
  • Roberson E. D., Halabisky B., Yoo J. W. et al. (2011) Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J. Neurosci. 31, 700711.
  • Shankar G. M., Bloodgood B. L., Townsend M., Walsh D. M., Selkoe D. J. and Sabatini B. L. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 28662875.
  • Shankar G. M., Li S., Mehta T. H. et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 14, 837842.
  • Shankar G. M., Leissring M. A., Adame A., Sun X., Spooner E., Masliah E., Selkoe D. J., Lemere C. A. and Walsh D. M. (2009) Biochemical and immunohistochemical analysis of an Alzheimer’s disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol. Dis. 36, 293302.
  • Simon A. M., de Maturana R. L., Ricobaraza A. et al. (2009) Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer’s disease. J. Alzheimers Dis. 17, 773786.
  • Snyder E. M., Nong Y., Almeida C. G. et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 10511058.
  • Sturchler E., Galichet A., Weibel M., Leclerc E. and Heizmann C. W. (2008) Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 28, 51495158.
  • Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R., Hill R., Hansen L. A. and Katzman R. (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572580.
  • Tomiyama T., Nagata T., Shimada H. et al. (2008) A new amyloid beta variant favoring oligomerization in Alzheimer’s-type dementia. Ann. Neurol. 63, 377387.
  • Tomiyama T., Matsuyama S., Iso H. et al. (2010) A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 30, 48454856.
  • Townsend M., Shankar G. M., Mehta T., Walsh D. M. and Selkoe D. J. (2006) Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572, 477492.
  • Vodopivec I., Galichet A., Knobloch M., Bierhaus A., Heizmann C. W. and Nitsch R. M. (2009) RAGE does not affect amyloid pathology in transgenic ArcAbeta mice. Neurodegener. Dis. 6, 270280.
  • Walsh D. M., Tseng B. P., Rydel R. E., Podlisny M. B. and Selkoe D. J. (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39, 1083110839.
  • Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J. and Selkoe D. J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535539.
  • Walsh D. M., Townsend M., Podlisny M. B., Shankar G. M., Fadeeva J. V., El Agnaf O., Hartley D. M. and Selkoe D. J. (2005) Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci. 25, 24552462.
  • Westerman M. A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L. H., Carlson G. A., Younkin S. G. and Ashe K. H. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer’s disease. J. Neurosci. 22, 18581867.
  • Wilcox K. C., Lacor P. N., Pitt J. and Klein W. L. (2011) Abeta oligomer-induced synapse degeneration in Alzheimer’s disease. Cell. Mol. Neurobiol. 31, 939948.
  • Yan S. D., Chen X., Fu J. et al. (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 382, 685691.
  • Yu W., Zou K., Gong J. S., Ko M., Yanagisawa K. and Michikawa M. (2005) Oligomerization of amyloid beta-protein occurs during the isolation of lipid rafts. J. Neurosci. Res. 80, 114119.
  • Zempel H., Thies E., Mandelkow E. and Mandelkow E. M. (2010) Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 30, 1193811950.